Active Filter(s):
Details:
The financing will advance the development of Osteal’s portfolio of therapies, including the submission of NDA and accelerated commercial launch of VT-X7 for treating PJI of the hip and knee.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series D Financing June 05, 2024
Details:
VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJI).
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
The proceeds will support NDA submission and preparation for commercial launch of company's VT-X7, a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin hydrochloride and tobramycin, for periprosthetic joint infection.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Asteroid Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 21, 2023
Details:
VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJI).
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Musculoskeletal Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
VT-X7, (Vancomycin Hydrochloride), a drug/device combination product that locally delivers, via irrigation, highly targeted antibiotic therapy to the hip or knee during an accelerated seven-day interstage period of a two-stage exchange arthroplasty.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin
Therapeutic Area: Musculoskeletal Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: HM Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 08, 2022